

varian

Dielectric Lasers and the future of radiosurgery

Eric Abel

Manager, Translational Science



Varian Legacy



varian

Vision:

**A World Without
Fear of Cancer**



Varian today – a snapshot

Global Leader in radiation therapy	>7,000 employees	>3M Cancer patients touched/year	\$2.9B FY18 revenues
A focused cancer company			
>8,000 medical linear accelerators	5,000 software installs	70 proton therapy rooms	>40 worldwide training centers

Cancer affects everyone



24.6 Million

New Cancer Cases by 2030



\$2 Trillion

Global Economic Burden in 2010



50 - 60%

Cancer Patients Requiring RT



56%

Cancers Diagnosed In
High Income Countries



10%

Cancer Patients That Have Access
To RT in Low Income Countries



> 20,000*

Linacs needed by 2035; greatest
need in low + mid-income countries

5
*8,700 new machines plus 13,100 replacements = 21,800 additional machines needed
Source: Expanding global access to radiotherapy. Lancet Oncol. Vol 16, Sept. 2015

WORLDWIDE CANCER BURDEN – A CALL TO ACTION



24.6M

new cancer cases diagnosed
per year by 2030*


A ~75% increase in cancer incidence from 2012**

*Expanding global access to radiotherapy. Lancet Oncol. Vol 16, Sept.2015

**Global cancer facts and figures, 3rd edition, ACS

VARIAN CONFIDENTIAL / PROPRIETARY · DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY


Cancer Treatment Pillars



VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY

varian

Cell Response to Radiation




VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY
FOR IMMEDIATE RECIPIENT ONLY

- Differential response of normal and cancer cells to radiation defines therapeutic window
- Therapeutic window can be enhanced through the use of **conformal radiation**

varian

Expanding the therapeutic window: Radiation



VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY

varian

State of the art “Photon” Therapy Systems

Photon delivery platforms


C-arm



Robotic




Closed Bore




State of the art proton therapy systems

Proton center configurations

Multi-room



Single Room




Gantry Mounted Cyclotron




Radiosurgery - VMAT

Multiple Brain Metastases



State-of-the-art Proton Therapy

Intensity Modulated Proton Therapy (IMPT)



VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY

varian

What about 2019 and beyond?

A look to the future of radio therapy


- Therapeutic window optimization through conformal dose shaping is reaching an asymptote
- Further enhancements can come from
 - Novel delivery paradigms (FLASH, SFRT)
 - Combination therapies (RT modulated immunotherapy, RT sensitizers)

What about 2019 and beyond?

A look to the future of radio therapy


- Therapeutic window optimization through conformal dose shaping is reaching an asymptote
- Further enhancements can come from
 - Novel delivery paradigms (FLASH, SFRT)
 - Combination therapies (RT modulated immunotherapy, RT sensitizers)

Flash (ultra high dose rate) spares normal tissue




**NORMAL
TISSUE**

Control
0 Gy/s



**SIGNIFICANT
FIBROSIS**


Standard RT 17 Gy
0.03 Gy/s



**NO APPARENT
DAMAGE**

FLASH 17 Gy
60 Gy/s

Increasing the effective ionizing radiation dose by **10%** could increase tumour control rates by **5-30%**




Therapeutic window

FLASH therapy promise:

- Improving Normal Tissue Complication Probability (NTCP)
- While maintaining Tumor Control Probability (TCP)
- Thereby widening the therapeutic window

Ultra high dose rates





Spatially Fractionated Radiation Therapy (SFRT)

Grid Therapy


Gantry Mounted Grid Block

Lower integral dose to normal tissue
allows for escalation of dose to tumor



SFRT

Minibeam/microbeam therapy



- Preclinical experiments showing that delivering dose in thin “sheets” spares normal tissue
- Tumor control is preserved resulting in enhancement of therapeutic window

What about 2019 and beyond?

A look to the future of radio therapy

- Therapeutic window optimization through conformal dose shaping is reaching an asymptote
- Further enhancements can come from
 - Novel delivery paradigms (FLASH, SFRT)
 - Combination therapies (RT modulated immunotherapy, RT sensitizers)

IMMUNITY CYCLE

Opportunities and challenges to eradicate cancer and the role of radiation

SEVEN


steps to complete the cycle from recognition to killing

THREE

compartments where the action takes place

TWO


opposing mechanism control advancement from one step to the next



varian

ABSCOPAL EFFECT

- Radiotherapy in one site can potentially eradicate tumors elsewhere




VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY
FOR IMMEDIATE RECIPIENT ONLY

Radiosensitizers

- Any compound which helps to enhance the therapeutic window of RT alone
- Can be a drug, or inert compound such as polymer or metal

Gold nanoparticles can “amplify” dose locally



Lasers in the clinic

Dielectric Laser Acceleration


Wakefield Acceleration

- Terawatt Lasers
- Ultrahigh electron gradients
- Short pulse, low duty cycle




Dielectric Laser Acceleration

- Benchtop laser
- Stageable
- Compact
- Low dose rate




Radiation Pressure Acceleration

- Petawatt lasers
- Sub-clinical proton energies
- Short pulse, low duty cycle



DLA – “Radioscalpel” of the future

Dream a little...



Advantages of DLA for Medical Applications :

- Compact, customizable
- Conducive to image guidance
- Potentially inexpensive
- Small beams
- Electron or x-ray possible
- Ideal for transition away from conformal therapy

VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY
FOR IMMEDIATE RECIPIENT ONLY

varian

DLA – Radioscalpel of the future

Dream a little...

Possible to treat smaller lesions with less toxicity (small early stage tumors)

Plus...

Possible novel (non-oncology) applications :

- Movement disorders, treat base of skull (2-3mm region)
- Keloids, the target is the skin (so appropriate for keloids).
- Alzheimers
- Cardiac
- Myasthenia gravis (back of the eye)

(Thank You)